心未来 为促进心血管医工合作、技术创新，思宇MedTech、心未来将于 2025年5月15日（星期四） ，在北京中关村展示中心举办 首届全球心血管大会 （GCC2025）暨创新颁奖典礼 。 报名从速，锁定参会席位~ （注：参会免费！ 前期填表的已拉群；没有入群的，请通过工作人员好友申请，方便后续发地址、会刊等。） 2025心血管创新白皮书目录 四、会议规模： 现场参会嘉宾500人 五、大会议程（暂定，持续更新中）： 首届全球心血管大会 Global Cardiovascular Conference 2025 暨2025行业颁奖典礼 一、活动时间： 2025年5月15日 星期四 9:00-12:30 （下午为政府闭门对接会，请希望参会的CEO私信 联系赵清微信号qingzhao2017 ） 二、活动地点： 中关村展示中心会议中心（新建宫门路2号） 三、主办单位： 心未来、思宇MedTech； 协办单位：中关村联新生物医药产业联盟，M edtec医疗器械设计与制造技术展览会 支持单位：启迪之星，中关村科学城CGT产业孵化中心 | | | 于洋,北京安贞医院科技处处长、成果转化办公室副主任; 心脏外科主任医师、教 ...

主办方： 思宇MedTech、中关村联新生物医药产业联盟 协办方： 北京通和立泰生物科技有限公司、中关村医疗器械园有限公司 路演时间 ： 2025年5月29日星期四下午14:00 路演形式： 线上，腾讯会议；现场路演 地点： 中关村医疗器械园 项目报名方式： 复制此链接到浏览器中填写。 https://docs.qq.com/form/page/DUFBzS2xteFh1ZUph 点击文末 "阅读原文" 填写报名表，或者复制链接到浏览器中填写。 或扫描二维码进行填写 （注：以上是CEO报名表。投资人报名通知会在路演前五天发出。） 思宇MedTech组织的项目路演特色： 1. 创始人为研发或医生背景，良好的教育和职业履历。 2. 参与的投资人是经过审核的、有相关投资案例的机构。 3. 项目可直接对接投资人，简单高效。 1 哪些项目可以报名？ 路演后续如何推进？ 1. 融资阶段：天使轮~C轮之间均可。 路演时，请项目方直接将联系方式留在PPT上，等待投资机构主动联系；我们也会帮投资人对接项目 CEO；或者把微信号发到投资人群中。 哪些投资人会参加路演？ 4 项目报名方式 2 2. 优先医院医生的科技成果转化项目。 ...

Core Viewpoint - The article emphasizes the importance of a comprehensive understanding of the medical and health ecosystem, highlighting the need for entrepreneurs to develop strategic thinking and innovative capabilities to navigate the complexities of the industry [4][11]. Group 1: Program Overview - The program aims to cultivate leadership talents in the medical and health sector by providing a robust academic support system, innovative platforms, and clinical transformation resources [6][9]. - It features a unique value engine methodology that focuses on collaborative efforts between academia and industry to enhance strategic vision and innovation capabilities [7][8]. Group 2: Course Benefits - The curriculum addresses trends, challenges, and innovations in the medical industry, helping participants understand the development trajectory and future direction of the sector [11]. - It explores how to create a sustainable growth strategy for enterprises in uncertain environments, emphasizing the importance of opportunity identification and risk avoidance [12][13]. Group 3: Curriculum Modules - The program includes modules on entrepreneurial thinking in uncertain times, macroeconomic growth logic, and strategic diagnosis for effective execution [16]. - It covers topics such as value discovery, business model design, and investment decision-making in the healthcare sector [17]. Group 4: Networking and Resources - The program facilitates connections with top-tier resources, including visits to leading hospitals and enterprises in the medical field, fostering collaboration and innovation [21]. - It offers opportunities for global learning experiences, including visits to renowned institutions in the United States and Europe [22].

Core Viewpoint - The article emphasizes the collaboration between doctors, CEOs, engineers, and investors to address challenges in medical device innovation through a workshop organized by Shanghai Jiao Tong University School of Medicine and its affiliated institutions [1][4]. Training Highlights - The workshop aims to merge medical pain points with engineering technology to create innovative medical products and facilitate results transformation [4]. - Participants will learn the Biodesign innovation methodology, which is a global leading model for medical engineering innovation, focusing on efficient transformation [5]. - The program includes insights into the medical device industry trends, practical empowerment through design thinking and interdisciplinary collaboration, and opportunities for project exposure to potential investors [5]. Target Audience - The workshop is suitable for various professionals, including doctors from different departments, engineering personnel from research institutions, industry and investment practitioners, and entrepreneurs interested in medical device innovation [5]. Course Structure - The two-day intensive training covers medical innovation and technology layout, innovation practice, team exercises, and discussions on the key paths from concept to market [6][10]. - The first day includes sessions on medical innovation, technology layout, and practical exercises to foster collaboration among participants [6][8]. - The second day focuses on innovation industrialization and funding pathways, including discussions on financing, government support policies, and investment opportunities [12][15]. Expert Faculty - The workshop features a team of distinguished experts from Shanghai Jiao Tong University, including leaders in biomedical engineering and medical technology innovation, who will share their insights and experiences [13][16]. Registration Information - The workshop is scheduled for June 21-22, 2025, at Shanghai Jiao Tong University School of Medicine, with a fee of 8999 yuan per person, covering course materials and refreshments [9][18].

Core Viewpoint - The medical technology industry is at a crossroads of breakthrough and reconstruction, with advancements in AI-assisted diagnosis, high-end intelligent diagnostic equipment, innovative medical materials, and regenerative medicine reshaping disease discovery, treatment, and management [1] Group 1: Conference Overview - The Second Global MedTech Conference will be held on July 17, 2025, at the Zhongguancun Exhibition Center in Beijing, aiming to promote the collaborative development of the global medical technology industry chain, innovation chain, and clinical application [1][4] - The first conference, Global MedTech Conference 2024, was organized by Siyu [2] Group 2: Awards and Recognition - The conference will present several awards to recognize breakthroughs in medical technology, including the 2025 Global MedTech Innovation Award and the 2025 Global MedTech Clinical Application Award [3][7] - The awards aim to honor innovative products or platform technologies with originality, advancement, and potential for large-scale industrialization [6] Group 3: Conference Agenda - Proposed agenda topics include analysis of global medical technology development trends and policy environments, research and transformation paths for imaging platforms, new consumables, brain-computer interfaces, interventional devices, and diagnostic equipment [5] - Other topics will cover AI-assisted diagnosis, digital therapy breakthroughs, and insights into technology directions and enterprise profiles that attract domestic and foreign capital [5] Group 4: Participation and Submission Process - Companies interested in participating in the awards must fill out a designated form and submit relevant documents by May 31, 2025 [9][10] - The evaluation phase will occur from June 1 to June 15, 2025, with results announced between June 16 and June 22, 2025 [10]

Core Viewpoint - The medical aesthetics industry is rapidly evolving, driven by advancements in material science, biotechnology, laser technology, and regenerative medicine, leading to a reshaping of the industry ecosystem. A global conference is scheduled for June 12, 2025, in Beijing to foster collaboration and innovation in this field [1]. Group 1: Conference Details - The "Global Aesthetic Technology Conference 2025" will take place at the Beijing Zhongguancun Exhibition Center [1]. - The conference aims to gather clinical experts, top scientists, innovators, investment institutions, and government regulators to discuss cutting-edge developments, commercialization paths, regulatory trends, and market opportunities in medical aesthetics [1]. - The expected attendance is around 500 participants from various sectors, including government, hospitals, and upstream and downstream enterprises in the medical aesthetics industry [1]. Group 2: Awards and Recognition - The conference will feature the "2025 Global Aesthetic Technology Innovation Awards" to recognize outstanding contributions in the medical aesthetics technology field [2]. - The awards will include categories such as: - **2025 Global Aesthetic Technology Innovation Award**: For companies and manufacturers demonstrating significant technological innovation with high clinical value [3]. - **2025 Global Aesthetic Clinical Excellence Award**: For products or technologies achieving notable results in clinical applications, receiving positive feedback from both doctors and clients [4]. - **2025 Global Aesthetic Industry Service Award**: For companies and institutions providing exceptional services in technology innovation, clinical trials, and manufacturing within the medical aesthetics sector [5][6]. - **2025 Global Aesthetic Innovation & Translation Award**: For individuals making significant innovative contributions in medical aesthetics, promoting products or solutions with industrialization potential [7]. Group 3: Award Application Process - The application phase for the awards is open from now until May 19, 2025, where companies can submit their materials [10]. - The evaluation phase will occur from May 20 to May 25, 2025, involving material review and expert evaluations [10]. - Winners will be notified between May 26 and May 30, 2025, with awards presented at the conference on June 12, 2025 [10].

报名：首届全球心血管大会 | 最新议程 合作伙伴征集：2025全球手术机器人大会 2025年5月9日，创新心血管医疗器械公司CorFlow Therapeutics宣布，任命Chris O'Connell为董事会主席，接替Rick Geoffrion的职务。 这一人事变动并不简单。Chris O'Connell的职业履历高度浓缩了 全球医疗器械"头部经验" ：他在 美敦力工作了21年 ，先后主导过心血管、糖尿病及修复治疗事 业部，是当年美敦力扩张黄金期的执行委员会核心成员；此后，又担任Waters Corporation总裁兼CEO五年，带领公司实现营收与市值的双重增长。 过去几年，Chris以独立董事身份出现在多家医疗器械与生命科学公司董事会中。但这一次，他选择在CorFlow"上桌"，担任董事会主席。 从一家全球巨头到一家术式仍在试验阶段的公司，这不是轻易的决定。 CorFlow究竟做了什么，让这样一位业内老将愿意下注？ # CoFI：从"术中看不见的MVO"，到实时诊断+局部治疗 CorFlow的核心平台为 Controlled Flow Infusion（CoFI）系统 ，聚焦于 微血管阻塞（MVO） ...

Core Viewpoint - Globus Medical reported a decline in net sales for Q1 2025, attributed to multiple factors including slowed technology transactions, supply chain disruptions, and fluctuations in international distributor orders, although the core U.S. spine business performed well [4][6]. Financial Performance - For Q1 2025, Globus Medical's global net sales were $598.1 million (approximately 4.3 billion RMB), a year-over-year decrease of 1.4%. On a constant currency basis, the decline was 0.8% [6]. - The GAAP net income for the quarter was $75.5 million, with a GAAP diluted earnings per share (EPS) of $0.54 and a non-GAAP diluted EPS of $0.68 [6]. - The company generated a record free cash flow of $141.2 million during the quarter and reaffirmed its full-year revenue guidance of $2.8 to $2.9 billion, while updating its non-GAAP EPS guidance to a range of $3.00 to $3.30 [6]. Mergers and Acquisitions - In February 2023, Globus Medical announced a $3.1 billion (approximately 21.1 billion RMB) acquisition of NuVasive, with NuVasive shareholders owning about 28% of the combined company post-transaction [4][7]. - The acquisition of Nevro for approximately $250 million was announced in early 2025, with a premium of 27% over Nevro's average stock price over the past 90 days [9][11]. Strategic Developments - The merger with NuVasive is expected to enhance the combined company's capabilities in the $50 billion global market for spine and orthopedic technologies, with analysts praising the integration as one of the most successful in the spine industry [7]. - The company launched 18 new products in 2024, including innovations that leverage the strengths of both companies, such as the ExcelsiusHub robotic platform integrated with Pulse neuro-monitoring technology [13]. Leadership Changes - In February 2025, the company announced that President Anthony L. Williams would leave by May 31, 2025, with CEO Dan Scavilla temporarily taking over the role to ensure operational stability during the transition [8].

Group 1: Tuberculosis Overview - Tuberculosis (TB) is a serious infectious disease caused by Mycobacterium tuberculosis, posing a significant global public health threat [3] - In 2021, China accounted for 7.4% of the global TB incidence, ranking third worldwide, with a treatment success rate for drug-resistant TB at only 53% compared to 95% for regular TB [3][6] - In 2021, there were 1.6 million deaths from TB globally, making it the 13th leading cause of death, just after COVID-19 [6] Group 2: Drug-Resistant Tuberculosis - The emergence of drug-resistant TB (MDR-TB and XDR-TB) complicates TB control efforts, leading to increased treatment difficulty, lower cure rates, and higher mortality [5] - In 2021, there were 450,000 new cases of MDR/RR-TB, with a treatment success rate of only 60% [6] Group 3: Limitations of Traditional Testing Methods - Traditional drug resistance testing methods are time-consuming, often taking weeks to months, and have low sensitivity and specificity [7] - Rapid molecular testing can provide quicker results but is limited in identifying a comprehensive range of drug resistance mutations [7] Group 4: Reversible Terminator Sequencing (RTS) - RTS is a high-precision DNA sequencing technology that allows for single-base resolution sequencing, significantly improving accuracy and sensitivity [8] - The technology is suitable for rapid diagnosis and clinical applications, completing the sequencing process in a short time [8] Group 5: Targeted Next-Generation Sequencing (tNGS) - tNGS integrates multiplex PCR/hybrid capture with next-generation sequencing, providing precise analysis of specific gene regions and comprehensive drug resistance information [9] - The tNGS method can analyze multiple antibiotic resistance genes simultaneously, aiding in early diagnosis and personalized treatment strategies [16] Group 6: Gold Standard Testing Kit - The Mycobacterium tuberculosis complex drug resistance gene mutation detection kit (RTS) combines tNGS with multiplex PCR, covering 13 resistance genes and over 200 mutation sites [13] - The kit can provide results in under 12 hours, with a sequencing run time of less than 5 hours, allowing for rapid detection of drug resistance [13] Group 7: Clinical Data and Performance - Clinical studies show that tNGS has an average consistency of 95.10% with phenotypic antimicrobial susceptibility testing (AST) and 97.05% with whole genome sequencing (WGS) [18] - In 158 bronchoalveolar lavage fluid samples, tNGS had a positivity rate of 87.95%, outperforming Xpert MTB/RIF [18] Group 8: Competitor Products - Cepheid's Xpert MTB/RIF offers rapid detection of Mycobacterium tuberculosis and rifampicin resistance with a sensitivity of 133 bacteria/mL, providing results in 2 hours [19] - Hain Lifescience's GenoType MTBDRplus uses linear probe hybridization for detecting TB and drug resistance, with a 48-hour turnaround time [20] - Becton Dickinson's BD MAX MDR-TB detects multiple drug resistance genes with high sensitivity and specificity, providing results in 2 hours [21] Group 9: Company Profile - Guangzhou Jinquirui Biotechnology Co., Ltd. focuses on the development, production, and sales of precision medical in vitro diagnostic products, established in 2016 [22] - The company has developed various technologies, including multiplex PCR and tNGS, and has received multiple core technology patents [24] - Jinquirui is one of the few companies in China providing a comprehensive solution for tumor and infection diagnostics, including gene sequencing instruments and clinical applications [24]

Core Viewpoint - Shanghai MicroPort Cardiac Interventional Medical Technology (Group) Co., Ltd. reported a decline in revenue and net profit for Q1 2025, indicating potential challenges in the company's financial performance and operational efficiency [2][6]. Financial Performance - The company's revenue for Q1 2025 was 332 million yuan, a year-on-year decrease of 7.23% [6]. - The net profit attributable to shareholders was 130 million yuan, down 29.66% year-on-year; the net profit excluding non-recurring items was 122 million yuan, a decline of 31.27% [6]. - Gross margin was 69.61%, down 6.90% year-on-year, while net margin was 38.53%, a decrease of 12.54% [6]. - Basic earnings per share were 1.05 yuan [6]. Expense Analysis - Total operating expenses (selling, administrative, and financial expenses) amounted to 63.01 million yuan, increasing from 9.72% to 18.97% of total revenue, a growth of 95.05% [7]. - Selling expenses rose by 68.09%, administrative expenses increased by 60.62%, while R&D expenses decreased by 31.26% and financial expenses grew by 56.24% [7]. Asset Status - As of the end of the reporting period, the company's cash and cash equivalents were 1.086 billion yuan, a decrease of 26.32% year-on-year [8]. - Accounts receivable stood at 355 million yuan, an increase of 83.78% year-on-year [8]. - Interest-bearing liabilities reached 152 million yuan, a significant increase of 1217.07% year-on-year [8]. Business Development - The company has made progress in the active artery intervention field, with several products receiving regulatory approvals and entering clinical trials [11][16]. - Key products include the Cratos® branched aortic stent system and Hector® thoracic aortic multi-branch stent system, both of which have received domestic approval [11]. - The company has subsidiaries focused on various interventional fields, enhancing its market presence and product offerings [15].